The company might just be the right kind of business operating at the right time in history.
Veteran medical device maker Penumbra (PEN 4.55%) got a shot of good news on Wednesday. An analyst initiated coverage of the company’s stock with a rather bullish review, and investors took this to heart. Collectively, they pushed Penumbra’s share price up by almost 5% on a day when the S&P 500 index performed sluggishly with a 0.3% decline.
Initiated with a buy recommendation
Just after market close on Tuesday, Stifel prognosticator Mathew Blackman set the tone for Penumbra on Wednesday. He launched his coverage of the specialty healthcare stock with an unambiguous buy recommendation, setting a price target of $238 per share. This anticipates rather juicy upside potential for the shares of nearly 22%.
In his inaugural analysis of Penumbra, Blackman offered several justifications for his bullish take. In terms of products, he singled out the mechanical thrombectomy segment, a company specialty, as a particularly ripe area for growth. He also feels the company is on solid ground fundamentally; he wrote that its “already cash-flow positive model, outsized growth, and margin profile are all significant points-of-differentiation.”
Finally, he is also encouraged by Penumbra’s “new product momentum” and its potential to exploit international markets.
Excellent timing
With all of these positive factors at its back, Penumbra is well positioned to experience sustained and meaningful growth in both sales and profitability, Blackman wrote. The company is indisputably operating at a very opportune time, when the overall U.S. population is getting proportionally older — and will be in greater need of health assistance and the products associated with medical care.